Latest News

AAI President Diana Moss testified at the Senate Judiciary Committee hearing on consolidation in the U.S. seed and agrochemical industry on September 20, 2016. Dr. Moss’s testimony reflects the AAI's long history of research, education, and advocacy on competition in agriculture and food. 

AAI President Diana Moss spoke recently at two separate events on airline and healthcare competition.

AAI’s Associate General Counsel Randy Stutz recently spoke at the 9th Seoul International Competition Forum in Seoul, Korea. The Seoul International Competition Forum is a biannual, global conference sponsored by the Korea Fair Trade Competition. Top government officials, competition experts from international organizations, and practitioners, academics, and others convened to discuss diverse subjects relating to competition law and policy.  Stutz participated in the morning panel on aftermarkets and delivered remarks on Effective Policing of Aftermarket Restraints Involving Intellectual Property.  

Public debate over the pricing of important drugs is gaining traction in the wake of the EpiPen controversy. The AAI has collected resources here on key competition issues surrounding branded and generic drugs. Mergers of branded and generic drug companies and strategic anticompetitive conduct by pharmaceutical companies can affect drug prices, choices, and innovation in these important markets, with direct and significant effects on consumers.

AAI’s resources on pharmaceutical competition range from a documentary film on generic drug manufacturer Mylan’s past conduct involving an anti-anxiety drug to analysis supporting opposition to the recently approved Teva-Allergan merger. Also included are certain AAI amicus briefs filed in federal court cases that unpack key issues surrounding the use of patent rights to shape and control competition. This legal-economic analysis covers strategic attempts to delay the entry of generic drugs (“pay-for-delay”) and to move consumers from older-generation drugs coming off patent to next generation branded drugs (“product-hopping”).

AAI President Diana Moss spoke in August at the 2016 annual conventions for the Organization for Competitive Markets and R-Calf USA. Her remarks highlighted growing concerns about declining competition in the United States, trends in antitrust enforcement during the Bush and Obama administrations, lower-than-average enforcement activity in the food and agriculture sectors, and major issues to watch.  The AAI will be issuing a chapter on food and agriculture as part of its Transition Report to the 45th President of the United States.